A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

NCT00000969 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

400

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Zalcitabine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]